BR112022007674A2 - Métodos para tratar doença de pompe, para melhorar a função muscular, para reduzir o acúmulo de glicogênio, para melhorar a função pulmonar e para aumentar a expressão de gaa, kits e usos de um vetor aav - Google Patents

Métodos para tratar doença de pompe, para melhorar a função muscular, para reduzir o acúmulo de glicogênio, para melhorar a função pulmonar e para aumentar a expressão de gaa, kits e usos de um vetor aav

Info

Publication number
BR112022007674A2
BR112022007674A2 BR112022007674A BR112022007674A BR112022007674A2 BR 112022007674 A2 BR112022007674 A2 BR 112022007674A2 BR 112022007674 A BR112022007674 A BR 112022007674A BR 112022007674 A BR112022007674 A BR 112022007674A BR 112022007674 A2 BR112022007674 A2 BR 112022007674A2
Authority
BR
Brazil
Prior art keywords
methods
improve
kits
function
aav vector
Prior art date
Application number
BR112022007674A
Other languages
English (en)
Inventor
T Gray John
Cunningham Justine
Rico Salvador
Original Assignee
Audentes Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Audentes Therapeutics Inc filed Critical Audentes Therapeutics Inc
Publication of BR112022007674A2 publication Critical patent/BR112022007674A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)

Abstract

MÉTODOS PARA TRATAR DOENÇA DE POMPE, PARA MELHORAR A FUNÇÃO MUSCULAR, PARA REDUZIR O ACÚMULO DE GLICOGÊNIO, PARA MELHORAR A FUNÇÃO PULMONAR E PARA AUMENTAR A EXPRESSÃO DE GAA, KITS E USOS DE UM VETOR AAV. A presente divulgação se refere a composições e métodos úteis para tratar distúrbios de armazenamento de glicogênio, como distúrbio de armazenamento de glicogênio tipo II, também denominado, no presente documento, doença de Pompe. Usando-se as composições e os métodos da divulgação, um paciente (por exemplo, um paciente mamífero, como um paciente humano) que tem a doença de Pompe pode ser administrado com um vetor viral, como um vetor viral adenoassociado (AAV), que contém um transgene que codifica alfa-glicosidase ácida.
BR112022007674A 2019-10-25 2020-10-23 Métodos para tratar doença de pompe, para melhorar a função muscular, para reduzir o acúmulo de glicogênio, para melhorar a função pulmonar e para aumentar a expressão de gaa, kits e usos de um vetor aav BR112022007674A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926282P 2019-10-25 2019-10-25
US202063083349P 2020-09-25 2020-09-25
PCT/US2020/057081 WO2021081338A1 (en) 2019-10-25 2020-10-23 Compositions and methods for treating glycogen storage disorders

Publications (1)

Publication Number Publication Date
BR112022007674A2 true BR112022007674A2 (pt) 2022-08-09

Family

ID=75620302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007674A BR112022007674A2 (pt) 2019-10-25 2020-10-23 Métodos para tratar doença de pompe, para melhorar a função muscular, para reduzir o acúmulo de glicogênio, para melhorar a função pulmonar e para aumentar a expressão de gaa, kits e usos de um vetor aav

Country Status (13)

Country Link
US (1) US20220387562A1 (pt)
EP (1) EP4048286A4 (pt)
JP (1) JP2022554141A (pt)
KR (1) KR20220105643A (pt)
CN (1) CN114828858A (pt)
AU (1) AU2020372429A1 (pt)
BR (1) BR112022007674A2 (pt)
CA (1) CA3158281A1 (pt)
CO (1) CO2022006772A2 (pt)
IL (1) IL292401A (pt)
MX (1) MX2022004799A (pt)
TW (1) TW202116359A (pt)
WO (1) WO2021081338A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240145491A (ko) * 2022-02-03 2024-10-07 아스텔라스 진 테라피스, 인크. 폼페병의 개선된 치료를 위한 조성물 및 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013192317A2 (en) * 2012-06-19 2013-12-27 University Of Florida Research Foundation, Inc. Compositions and methods for treating diabetes
EP3293260A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
US20210346519A1 (en) * 2018-02-07 2021-11-11 Genethon Hybrid regulatory elements

Also Published As

Publication number Publication date
JP2022554141A (ja) 2022-12-28
CA3158281A1 (en) 2021-04-29
IL292401A (en) 2022-06-01
CO2022006772A2 (es) 2022-08-09
WO2021081338A1 (en) 2021-04-29
MX2022004799A (es) 2022-07-19
AU2020372429A1 (en) 2022-04-28
KR20220105643A (ko) 2022-07-27
EP4048286A1 (en) 2022-08-31
EP4048286A4 (en) 2023-12-06
TW202116359A (zh) 2021-05-01
US20220387562A1 (en) 2022-12-08
CN114828858A (zh) 2022-07-29

Similar Documents

Publication Publication Date Title
Torres‐Espín et al. Bone marrow mesenchymal stromal cells and olfactory ensheathing cells transplantation after spinal cord injury–a morphological and functional comparison in rats
BR112021021156A2 (pt) Terapêuticos anticorpos totalmente humanos pós-tradução modificados
MX2021012184A (es) Terapias genicas para trastornos lisosomales.
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR0011823A (pt) Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
BR112022015979A2 (pt) Vetores de terapia genética para tratamento de doenças cardíacas
BR112014031788A2 (pt) composições e métodos para o tratamento de diabetes
BR112021021908A2 (pt) Composições úteis no tratamento da leucodistrofia metacromática
MX2021006253A (es) Terapias génicas para enfermedad neurodegenerativa.
BRPI1006104B8 (pt) gene isolado que codifica glucoquinase humana, vetor recombinante, hospedeiro, e, composição farmacêutica
Wang et al. Recombinant hNeuritin promotes structural and functional recovery of sciatic nerve injury in rats
BR112022008214A2 (pt) Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina
Ji et al. Hippocampal MSK1 regulates the behavioral and biological responses of mice to chronic social defeat stress: Involving of the BDNF-CREB signaling and neurogenesis
BR112022007674A2 (pt) Métodos para tratar doença de pompe, para melhorar a função muscular, para reduzir o acúmulo de glicogênio, para melhorar a função pulmonar e para aumentar a expressão de gaa, kits e usos de um vetor aav
WO2022076556A3 (en) Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
Fallahi et al. Genetic doping and health damages
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
KR20170009464A (ko) 헤마글루티닌-뉴라미니다아제와 f 단백질을 과발현하는 중간엽줄기세포 및 그 용도
BR112022000898A2 (pt) Terapia de gene cardíaco aav para cardiomiopatia em seres humanos
BR112022021468A2 (pt) Genes gla otimizados por códon e usos dos mesmos
Senthilkumar et al. Reversal of neuropsychiatric comorbidities in an animal model of temporal lobe epilepsy following systemic administration of dental pulp stem cells and bone marrow mesenchymal stem cells
BR112020004935A2 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular
BR0317132A (pt) Métodos de diagnóstico e tratamento de doença pulmonar intersticial
MX2023001562A (es) Terapias genicas para trastornos lisosomales.
Melman et al. Gene therapy in the management of erectile dysfunction (ED): past, present, and future